Showing results (1-10 of 14) with videos related to
Sort By:
Pageof 2
British Journal of Hospital Medicine (London, England : 2005)|October 10, 2013
Management of open fractures of the lower limbAdam M Ali, David Noyes, Lucy K CogswellBMC Cancer|March 4, 2016
The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblastsMelanie Mediavilla-Varela, Kingsley Boateng, David Noyes, et al.New Directions for Child and Adolescent Development|March 8, 2017
Improving Early Grade Reading Outcomes: Aprender a Ler in MozambiqueShirley Burchfield, Haiyan Hua, David Noyes, et al.Spine|August 18, 2006
Healos and bone marrow aspirate used for lumbar spine fusion: a case controlled study comparing healos with autograftDaniel Neen, David Noyes, Matthew Shaw, et al.Cancer Biology & Therapy|August 7, 2013
Antagonism of adenosine A2A receptor expressed by lung adenocarcinoma tumor cells and cancer associated fibroblasts inhibits their growthMelanie Mediavilla-Varela, Kimberly Luddy, David Noyes, et al.Neoplasia (New York, N.Y.)|June 6, 2017
A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor MicroenvironmentMelanie Mediavilla-Varela, Julio Castro, Alberto Chiappori, et al.Journal for Immunotherapy of Cancer|May 26, 2022
Tumor-associated Tregs obstruct antitumor immunity by promoting T cell dysfunction and restricting clonal diversity in tumor-infiltrating CD8+ T cellsDavid Noyes, Arup Bag, Saheed Oseni, et al.Annals of Surgical Oncology|November 15, 2006
A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV diseaseSophie Dessureault, David Noyes, David Lee, et al.The Journal of Surgical Research|April 28, 2005
A GM-CSF/CD40L producing cell augments anti-tumor T cell responsesSophie Dessureault, Marwan Alsarraj, Susan McCarthy, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 3, 2013
Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinomaBen C Creelan, Scott Antonia, David Noyes, et al.Pageof 2